Akkermansia Muciniphilia and Metabolic Side Effects of ADT

Obesity Clinical Trial

Official title:

The Role of Akkermansia Muciniphilia in Combating the Metabolic Effects of Androgen Deprivation Therapy in Men With Metastatic Prostate Cancer

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05802121
• Other study ID #: ReDA ID 12558
• Status: Not yet recruiting
• Phase: Early Phase 1
• Start date: June 2023
• Est. completion date: June 2026

Study information

• Verified date: March 2023
• Source: Western University
• Contact: Kaydee Connors
• Phone: 519-685-8500
• Email: kaydee.connors[@]lhsc.on.ca
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The overriding objectives of this study are:

1. Primary outcomes:

1. To confirm that administration of oral acetate increases the proportion of A. muciniphilia in the stool samples of patients with metastatic, castration-sensitive prostate cancer compared to placebo.

2. To confirm tolerability and assess for side effects of delayed oral acetate supplementation.

2. Secondary outcomes:

1. To determine if increased counts of A. muciniphilia correlate with improved metabolic parameters and improved bone health.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 30
• Est. completion date: June 2026
• Est. primary completion date: June 2025
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 18 Years and older

Eligibility

For inclusion in this study, patients must fulfill all of the following criteria:

1. Men =18 years of age with histologically-proven metastatic castration-sensitive prostate adenocarcinoma planned to receive ADT (TNM stage Tany, Nany, M1) (see Appendix I).

2. Must have baseline conventional imaging with CT of the abdomen, and pelvis and bone scan.

Exclusion Criteria:

Patients fulfilling any of the following criteria are NOT eligible for participation in this study:

1. Age less than 18

2. Primary neuroendocrine prostate cancer

3. Treatment with ADT within the year leading up to enrolment

4. Unable to provide informed consent or unable to understand or read the English language (unless accompanied by an interpreter)

5. Inadequate liver function

Related Conditions & MeSH terms

• Bone Diseases
• Cardiovascular Morbidity
• Diabetes
• Hyperlipidemias
• Metabolic Syndrome
• Obesity
• Prostate Cancer
• Prostatic Neoplasms

Intervention

Drug:
• Apple Cider Vinegar
Each patient will be instructed to take 6 enteric slow-release acetate capsules (equivalent of 500 mg/ capsule containing 25 mg acetate x 6 capsules) per day for 3 months https://www.webbernaturals.com/en-ca/apple-cider-vinegar-500-mg-capsules/
• Placebo
Each patient will be instructed to take 6 placebo capsules per day for 3 months

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Western University

References & Publications (26)

Arrieta MC, Bistritz L, Meddings JB. Alterations in intestinal permeability. Gut. 2006 Oct;55(10):1512-20. doi: 10.1136/gut.2005.085373. No abstract available. — View Citation

Booth SL, Tucker KL, Chen H, Hannan MT, Gagnon DR, Cupples LA, Wilson PW, Ordovas J, Schaefer EJ, Dawson-Hughes B, Kiel DP. Dietary vitamin K intakes are associated with hip fracture but not with bone mineral density in elderly men and women. Am J Clin Nutr. 2000 May;71(5):1201-8. doi: 10.1093/ajcn/71.5.1201. — View Citation

Braga-Basaria M, Dobs AS, Muller DC, Carducci MA, John M, Egan J, Basaria S. Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy. J Clin Oncol. 2006 Aug 20;24(24):3979-83. doi: 10.1200/JCO.2006.05.9741. — View Citation

D'Amico AV, Denham JW, Crook J, Chen MH, Goldhaber SZ, Lamb DS, Joseph D, Tai KH, Malone S, Ludgate C, Steigler A, Kantoff PW. Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions. J Clin Oncol. 2007 Jun 10;25(17):2420-5. doi: 10.1200/JCO.2006.09.3369. — View Citation

Daisley BA, Chanyi RM, Abdur-Rashid K, Al KF, Gibbons S, Chmiel JA, Wilcox H, Reid G, Anderson A, Dewar M, Nair SM, Chin J, Burton JP. Abiraterone acetate preferentially enriches for the gut commensal Akkermansia muciniphila in castrate-resistant prostate cancer patients. Nat Commun. 2020 Sep 24;11(1):4822. doi: 10.1038/s41467-020-18649-5. Erratum In: Nat Commun. 2020 Dec 9;11(1):6394. — View Citation

Efstathiou JA, Bae K, Shipley WU, Hanks GE, Pilepich MV, Sandler HM, Smith MR. Cardiovascular mortality after androgen deprivation therapy for locally advanced prostate cancer: RTOG 85-31. J Clin Oncol. 2009 Jan 1;27(1):92-9. doi: 10.1200/JCO.2007.12.3752. Epub 2008 Dec 1. — View Citation

Evenepoel P, Dejongh S, Verbeke K, Meijers B. The Role of Gut Dysbiosis in the Bone-Vascular Axis in Chronic Kidney Disease. Toxins (Basel). 2020 Apr 29;12(5):285. doi: 10.3390/toxins12050285. — View Citation

Everard A, Belzer C, Geurts L, Ouwerkerk JP, Druart C, Bindels LB, Guiot Y, Derrien M, Muccioli GG, Delzenne NM, de Vos WM, Cani PD. Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity. Proc Natl Acad Sci U S A. 2013 May 28;110(22):9066-71. doi: 10.1073/pnas.1219451110. Epub 2013 May 13. — View Citation

Grossmann M, Hamilton EJ, Gilfillan C, Bolton D, Joon DL, Zajac JD. Bone and metabolic health in patients with non-metastatic prostate cancer who are receiving androgen deprivation therapy. Med J Aust. 2011 Mar 21;194(6):301-6. doi: 10.5694/j.1326-5377.2011.tb02979.x. — View Citation

Jespersen CG, Norgaard M, Borre M. Androgen-deprivation therapy in treatment of prostate cancer and risk of myocardial infarction and stroke: a nationwide Danish population-based cohort study. Eur Urol. 2014 Apr;65(4):704-9. doi: 10.1016/j.eururo.2013.02.002. Epub 2013 Feb 12. — View Citation

Keating NL, O'Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol. 2006 Sep 20;24(27):4448-56. doi: 10.1200/JCO.2006.06.2497. — View Citation

Kokorovic A, So AI, Serag H, French C, Hamilton RJ, Izard JP, Nayak JG, Pouliot F, Saad F, Shayegan B, Aprikian A, Rendon RA. Canadian Urological Association guideline on androgen deprivation therapy: Adverse events and management strategies. Can Urol Assoc J. 2021 Jun;15(6):E307-E322. doi: 10.5489/cuaj.7355. No abstract available. Erratum In: Can Urol Assoc J. 2021 Jul;15(7):E383. — View Citation

Luna M, Guss JD, Vasquez-Bolanos LS, Castaneda M, Rojas MV, Strong JM, Alabi DA, Dornevil SD, Nixon JC, Taylor EA, Donnelly E, Fu X, Shea MK, Booth SL, Bicalho R, Hernandez CJ. Components of the Gut Microbiome That Influence Bone Tissue-Level Strength. J Bone Miner Res. 2021 Sep;36(9):1823-1834. doi: 10.1002/jbmr.4341. Epub 2021 Jun 4. — View Citation

Mandatori D, Pelusi L, Schiavone V, Pipino C, Di Pietro N, Pandolfi A. The Dual Role of Vitamin K2 in "Bone-Vascular Crosstalk": Opposite Effects on Bone Loss and Vascular Calcification. Nutrients. 2021 Apr 7;13(4):1222. doi: 10.3390/nu13041222. — View Citation

McKay RR, Feng FY, Wang AY, Wallis CJD, Moses KA. Recent Advances in the Management of High-Risk Localized Prostate Cancer: Local Therapy, Systemic Therapy, and Biomarkers to Guide Treatment Decisions. Am Soc Clin Oncol Educ Book. 2020 May;40:1-12. doi: 10.1200/EDBK_279459. — View Citation

Morote J, Orsola A, Abascal JM, Planas J, Trilla E, Raventos CX, Cecchini L, Encabo G, Reventos J. Bone mineral density changes in patients with prostate cancer during the first 2 years of androgen suppression. J Urol. 2006 May;175(5):1679-83; discussion 1683. doi: 10.1016/S0022-5347(05)00999-7. — View Citation

Perraudeau F, McMurdie P, Bullard J, Cheng A, Cutcliffe C, Deo A, Eid J, Gines J, Iyer M, Justice N, Loo WT, Nemchek M, Schicklberger M, Souza M, Stoneburner B, Tyagi S, Kolterman O. Improvements to postprandial glucose control in subjects with type 2 diabetes: a multicenter, double blind, randomized placebo-controlled trial of a novel probiotic formulation. BMJ Open Diabetes Res Care. 2020 Jul;8(1):e001319. doi: 10.1136/bmjdrc-2020-001319. — View Citation

Saigal CS, Gore JL, Krupski TL, Hanley J, Schonlau M, Litwin MS; Urologic Diseases in America Project. Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer. Cancer. 2007 Oct 1;110(7):1493-500. doi: 10.1002/cncr.22933. — View Citation

Seible DM, Gu X, Hyatt AS, Beard CJ, Choueiri TK, Efstathiou JA, Miyamoto DT, Mitin T, Martin NE, Sweeney CJ, Trinh QD, Beckman JA, Basaria S, Nguyen PL. Weight gain on androgen deprivation therapy: which patients are at highest risk? Urology. 2014 Jun;83(6):1316-21. doi: 10.1016/j.urology.2014.02.006. Epub 2014 Apr 13. — View Citation

Smith MR, Finkelstein JS, McGovern FJ, Zietman AL, Fallon MA, Schoenfeld DA, Kantoff PW. Changes in body composition during androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab. 2002 Feb;87(2):599-603. doi: 10.1210/jcem.87.2.8299. — View Citation

Smith MR, Lee WC, Brandman J, Wang Q, Botteman M, Pashos CL. Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer. J Clin Oncol. 2005 Nov 1;23(31):7897-903. doi: 10.1200/JCO.2004.00.6908. — View Citation

Sturgeon KM, Deng L, Bluethmann SM, Zhou S, Trifiletti DM, Jiang C, Kelly SP, Zaorsky NG. A population-based study of cardiovascular disease mortality risk in US cancer patients. Eur Heart J. 2019 Dec 21;40(48):3889-3897. doi: 10.1093/eurheartj/ehz766. — View Citation

Timilshina N, Breunis H, Alibhai SM. Impact of androgen deprivation therapy on weight gain differs by age in men with nonmetastatic prostate cancer. J Urol. 2012 Dec;188(6):2183-8. doi: 10.1016/j.juro.2012.08.018. Epub 2012 Oct 18. — View Citation

van der Beek CM, Canfora EE, Lenaerts K, Troost FJ, Damink SWMO, Holst JJ, Masclee AAM, Dejong CHC, Blaak EE. Distal, not proximal, colonic acetate infusions promote fat oxidation and improve metabolic markers in overweight/obese men. Clin Sci (Lond). 2016 Nov 1;130(22):2073-2082. doi: 10.1042/CS20160263. Epub 2016 Jul 20. — View Citation

Voog JC, Paulus R, Shipley WU, Smith MR, McGowan DG, Jones CU, Bahary JP, Zeitzer KL, Souhami L, Leibenhaut MH, Rotman M, Husain SM, Gore E, Raben A, Chafe S, Sandler HM, Efstathiou JA. Cardiovascular Mortality Following Short-term Androgen Deprivation in Clinically Localized Prostate Cancer: An Analysis of RTOG 94-08. Eur Urol. 2016 Feb;69(2):204-10. doi: 10.1016/j.eururo.2015.08.027. Epub 2015 Sep 9. — View Citation

Zhou Q, Zhang Y, Wang X, Yang R, Zhu X, Zhang Y, Chen C, Yuan H, Yang Z, Sun L. Gut bacteria Akkermansia is associated with reduced risk of obesity: evidence from the American Gut Project. Nutr Metab (Lond). 2020 Oct 22;17:90. doi: 10.1186/s12986-020-00516-1. eCollection 2020. — View Citation

* Note: There are 26 references in all — Click here to view all references

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Fecal Akkermansia muciniphilia counts	Counts of Akkermansia muciniphilia in participant stool samples at 1 week following the intervention will be compared to baseline counts.	1 week
Primary	Fecal Akkermansia muciniphilia counts	Counts of Akkermansia muciniphilia in participant stool samples at 1 month following the intervention will be compared to baseline counts.	1 month
Primary	Fecal Akkermansia muciniphilia counts	Counts of Akkermansia muciniphilia in participant stool samples at 3 months following the intervention will be compared to baseline counts.	3 month
Primary	Fecal Akkermansia muciniphilia counts	Counts of Akkermansia muciniphilia in participant stool samples at 4 months following the intervention will be compared to baseline counts.	4 month
Primary	Fecal Akkermansia muciniphilia counts	Counts of Akkermansia muciniphilia in participant stool samples at 6 months following the intervention will be compared to baseline counts.	6 month
Primary	Side effects and tolerability	We will record side effects reported by the participants and the rate of Discontinuation of the intervention.	3 months
Secondary	Metabolic parameters: fasting plasma glucose	Fasting plasma glucose (mmol/L)	3 months
Secondary	Metabolic parameters: fasting plasma glucose	Fasting plasma glucose (mmol/L)	6 months
Secondary	Metabolic parameters: HbA1C	HbA1c (%)	3 months
Secondary	Metabolic parameters: HbA1c	HbA1c (%)	6 months
Secondary	Metabolic parameters: triglycerides	Triglycerides (mmol/L)	3 months
Secondary	Metabolic parameters: triglycerides	Triglycerides (mmol/L)	6 months
Secondary	Metabolic parameters: LDL cholesterol	LDL cholesterol (mmol/L)	3 months
Secondary	Metabolic parameters: LDL cholesterol	LDL cholesterol (mmol/L)	6 months
Secondary	Metabolic parameters: HDL cholesterol	HDL cholesterol (mmol/L)	3 months
Secondary	Metabolic parameters: HDL cholesterol	HDL cholesterol (mmol/L)	6 months
Secondary	Metabolic parameters: total cholesterol	Total cholesterol (mmol/L)	3 months
Secondary	Metabolic parameters: total cholesterol	Total cholesterol (mmol/L)	6 months
Secondary	Metabolic parameters: PSA	PSA (ng/mL)	6 months
Secondary	Metabolic parameters: PSA	PSA (ng/mL)	3 months
Secondary	Metabolic parameters: hemoglobin	Hemoglobin (g/L)	3 months
Secondary	Metabolic parameters: hemoglobin	Hemoglobin (g/L)	6 months
Secondary	Metabolic parameters: serum creatinine	Serum creatinine (µmol/L)	3 months
Secondary	Metabolic parameters: serum calcium	Serum calcium (µmol/L)	3 months
Secondary	Metabolic parameters: serum calcium	Serum calcium (µmol/L)	6 months
Secondary	Metabolic parameters: alanine transferase	Alanine transferase (U/L)	3 months
Secondary	Metabolic parameters: alanine transferase	Alanine transferase (U/L)	6 months
Secondary	Metabolic parameters: aspartate aminotransferase	Aspartate aminotransferase (U/L)	3 months
Secondary	Metabolic parameters: aspartate aminotransferase	Aspartate aminotransferase (U/L)	6 months
Secondary	Metabolic parameters: Insulin resistance index (HOMA IR)	Insulin resistance index (HOMA IR)	3 months
Secondary	Metabolic parameters: HOMA IR	Insulin resistance index (HOMA IR)	6 months
Secondary	Bone health: dp-ucMGP levels	Circulating plasma dp-ucMGP levels (surrogate for vitamin K2 levels) from baseline	3 months
Secondary	Bone health: dp-ucMGP levels	Circulating plasma dp-ucMGP levels (surrogate for vitamin K2 levels) from baseline	6 months
Secondary	Bone health: Vitamin K2	Vitamin K2 levels	3 months
Secondary	Bone health: Vitamin K2	Vitamin K2 levels	6 months